Zydus Lifesciences gains on getting EIR for Ankleshwar API manufacturing facility from USFDA
Zydus Lifesciences is currently trading at Rs. 982.30, up by 3.55 points or 0.36% from its previous closing of Rs. 978.75 on the BSE.
The scrip opened at Rs. 997.95 and has touched a high and low of Rs. 997.95 and Rs. 972.80 respectively. So far 55479 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1323.90 on 09-Aug-2024 and a 52 week low of Rs. 797.05 on 07-Apr-2025.
Last one week high and low of the scrip stood at Rs. 997.95 and Rs. 949.25 respectively. The current market cap of the company is Rs. 98314.09 crore.
The promoters holding in the company stood at 74.99%, while Institutions and Non-Institutions held 18.33% and 6.68% respectively.
Zydus Lifesciences has received the Establishment Inspection Report (EIR) from United States Food and Drug Administration (USFDA) for the inspection conducted at its API manufacturing facility located at Ankleshwar. This facility underwent an inspection from March 10, 2025 to March 14, 2025 and the inspection has been classified as No Action Indicated (NAI). The USFDA has concluded that this inspection is ‘closed’.
Zydus Lifesciences (formerly known as Cadila Healthcare), a company limited by shares, incorporated and domiciled in India, operates as an integrated pharmaceutical company with business encompassing the entire value chain in the research, development, production, marketing and distribution of pharmaceutical products.
